Kyoto University

Arkray, Inc.

Nihon Medi-Physics Company, Limited

Canon Kabushiki Kaisha

Shimadzu Corporation

National Hospital Organization

Fuji Photo Film Company, Limited

Fujifilm Corporation

Sumitomo Chemical Company, Limited

Suntory Holdings Limited

Hideo Saji

Hiroyuki Kimura

Hirokazu Matsuda

Masahiro Ono

Nobuya Inagaki

Kentaro Toyoda

Konomu Hirao

Kenji Nagakawa

Ikuya Seki

Akira Yokoyama

Satoshi Ogawa

Fumio Yamauchi

Kengo Kanazaki

Eiichi Ozeki

Yuki Okumura

Tsutomu Abe

Shunsaku Kimura

Akira Makino

Isao Hara

Kei Akama

Yasuhiro Magata

Yurie Fukui

Miho Ikenaga

Akihiro Izawa

Yoshihiro Doi

Nobuya Kobashi

Mitsuhide Naruse

Shuichi Nakanishi

Kohei Sano

Masafumi Ihara

Takashi Temma

Tatsuki Fukui

Keiko Shimamoto

Hiroki Matsumoto

Masami Okuno

Masamichi Satoh

Takayuki Nakagawa

Hisashi Tanaka

Yu Ogawa

Yuji Kuge

Masashi Ueda

Anna Miyazaki

Kazuko Horiuchi Suzuki

Yoshiro Omomo

Iwoa Nakatsuka

Mikako Ioroi

Asami Kon

To provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), Rrepresents any of a residue or a functional group derived from a cationic polymerization initiator; L represents a linker and L may not be present; n represents an integer of 1 or more; D represents a dye backbone of a dye having absorption in the near-infrared region.

Polymer, and contrast agent for photoacoustic imaging, including the polymer

An object is to provide a polymer having a high tumor/blood ratio. The present invention provides a polymer represented by the following formula (P1): wherein in the formula (P1), R represents any of a residue derived from a polymerization initiator, or a functional group; A may not be present, and when present, A represents any of a low-molecular compound, a dye, a reporter molecule, a target-binding molecule, a polymer or D; L represents a linker and L may not be present; nrepresents an integer of 1 or more; and D represents a dye backbone of a dye having absorption in the near-infrared region.

Conjugate of polysarcosine and NIR contrast agent for photoacoustic imaging

Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where R, R, and Y are as defined. 

Nuclear medicine diagnostic imaging agent

Provided is a medicament comprising the compound represented by the following general formula (1) or a salt thereof: In the formula, R, R, R, R, R, X, X, and Xare defined. Methods for producing various radioactive compounds are also provided.

2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same

Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R, R, R, R, R, X, X, and Xare defined.

2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same

The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Radioactive halogen-labeled pyrido [1,2-A] benzimidazole derivative compound

The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.

Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound

Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where Y, L, Rand Rare as defined. 

A peptide that can be used as an imaging probe for GLP-1R is provided. In an embodiment, a polypeptide is represented by the following formula (3); 

Polypeptide and imaging method

[Problem] To provide a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye in a blood component and emit fluorescence in a tumor or an inflamed site to be imaged). [Solution] A fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a polylactic acid-bound cyanine compound comprising: a fluorescent group represented by the formula (I): and a polylactic acid group having 5 to 50 lactic acid units, and two or more molecules of the fluorescent dye are encapsulated in the single molecular assembly.

Switching-type fluorescent nanoparticle probe, and fluorescent molecular imaging method using same

The present invention provides a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye during nanoparticle preparation, and emit fluorescence during imaging). A switching fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a cyanine compound represented by the formula (I): and two or more molecules of the fluorescent dye are encapsulated in the single molecular assembly.

Switching fluorescent nanoparticle probe and fluorescent particle imaging method using same

A new peptide derivative is provided. The peptide derivative is represented by the following general formula (I), where polypeptide ExP is polypeptide that contains completely or partially the amino acid sequence of exendin-4, and a -L-Z group represents a group represented by the following formula (II) that is bonded to an amino acid side chain of or the &#x3b1;-amino group at the N-terminus of the polypeptide ExP, 

Peptide derivative and use of the same

A molecular probe for imaging of pancreatic islets is provided. The molecular probe includes a polypeptide represented by the following formula (1), or a polypeptide that has a homology with the foregoing polypeptide. Wherein 'X' represents a lysine residue, an amino group of a side chain of the lysine residue being labeled with a group represented by the following chemical formula (I), wherein A represents an aromatic hydrocarbon group or an aromatic heterocyclic group; Rrepresents a substituent that containsC,N,O,F,Cu,Ga,Ga,Br,Br,Br,Tc,In,I,I,I, orI; Rrepresents either a hydrogen atom, or a substituent different from that represented by R; and Rrepresents any one of a bond, an alkylene group having 1 to 6 carbon atoms, and an oxyalkylene group having 1 to 6 carbon atoms.

Molecular probe for imaging of pancreatic islets and use of the same

A precursor of a molecular probe for imaging of pancreatic islets is provided. The precursor includes a polypeptide represented by any one of the following formulae (1) to (12), or a polypeptide having a homology with the foregoing polypeptide: 

Molecular probe precursor for imaging of pancreatic islet, and use thereof

Embodiments of the invention provide a compound accumulating in an inflammatory site, a diagnostic agent containing the compound in labeled state and its precursor compound for labeling. Such a compound accumulating in inflammatory site may be represented by the following formula (1):Z&#x2014;Y-Leu-Phe-(X)-Lys(-(Lys)-HalB)-(Lys)-NH&#x2003;&#x2003;(1)

Compound accumulating in inflammatory site, diagnostic agent containing the compound in labeled state and its precursor compound for labeling

Growing community of inventors

Kyoto, Japan

Hideo Saji